Notably, our previous study indicated that sodium-glucose cotransporter 2 (SGLT2) inhibitors and renin-angiotensin-aldosterone system inhibitors were not routinely used in more than 66% and 77% of the DKD patients we followed, respectively (21). This evidence concerns the gene REN and diabetic kidney disease.